Aim: The prognosis of chronic hepatitis C clinical courseMethods: The HLA AG of A, B, C locuses was investigated in 11 patients with chronic hepatitis C (CHC) by the method of complement/dependent cytotoxicity.Results: Locuses B were found: B35 in 41 (6% of cases), B5 – in 27 (2%), while locuses A: A2 – in 27, (2%) and A10 – in 27, (2%). The comparison between basic markers of main liver syndromes (cytolitic, cholestatic, hepatodepressive, immune inflammation) and the phenotypes variants in patients with CH C was carried out. The cytolisis was more expressed in patients with HLA B35 (ALT – 154.03±4.59μ/l, AST – 110.21±5.40μ/l). The increasing of CIC level (371.66±16,1UDO), decreasing of T-tot lymphocytes to 616.5±35,0;43,83%±0,98 and T-sup (194,50±4,24; 12,50%±0,54) with increasing of T-help/T-sup ratio to 2,17 were found simultaneously. Meanwhile in patients with HLA A2, B5 were found minimal clinical manifestations: almost normal CIC levels, increasing of IgG, decreasing of T-tot, T-help with increasing of T-sup and lowering of T-help/T-sup indices to 0.29 and 0.36, correspondingly. Moderate cytolitic syndrome with simultaneous tension of humoral immune answer (>CIC, >IgG, IgM) on the background of moderate T-tot and T-sup lymphocytes decreasing, increasing of T-help account and T-help/T-sup index (3,76) were characteristic to the carries of HLA A10.Conclusion: These data may have the important significance for prognosis of clinical course, grade of liver disease and estimation of risk groups of patients with HCV hepatitis for autoimmune disorders that are extremely important in the case of antiviral therapy Aim: The prognosis of chronic hepatitis C clinical course Methods: The HLA AG of A, B, C locuses was investigated in 11 patients with chronic hepatitis C (CHC) by the method of complement/dependent cytotoxicity. Results: Locuses B were found: B35 in 41 (6% of cases), B5 – in 27 (2%), while locuses A: A2 – in 27, (2%) and A10 – in 27, (2%). The comparison between basic markers of main liver syndromes (cytolitic, cholestatic, hepatodepressive, immune inflammation) and the phenotypes variants in patients with CH C was carried out. The cytolisis was more expressed in patients with HLA B35 (ALT – 154.03±4.59μ/l, AST – 110.21±5.40μ/l). The increasing of CIC level (371.66±16,1UDO), decreasing of T-tot lymphocytes to 616.5±35,0;43,83%±0,98 and T-sup (194,50±4,24; 12,50%±0,54) with increasing of T-help/T-sup ratio to 2,17 were found simultaneously. Meanwhile in patients with HLA A2, B5 were found minimal clinical manifestations: almost normal CIC levels, increasing of IgG, decreasing of T-tot, T-help with increasing of T-sup and lowering of T-help/T-sup indices to 0.29 and 0.36, correspondingly. Moderate cytolitic syndrome with simultaneous tension of humoral immune answer (>CIC, >IgG, IgM) on the background of moderate T-tot and T-sup lymphocytes decreasing, increasing of T-help account and T-help/T-sup index (3,76) were characteristic to the carries of HLA A10. Conclusion: These data may have the important significance for prognosis of clinical course, grade of liver disease and estimation of risk groups of patients with HCV hepatitis for autoimmune disorders that are extremely important in the case of antiviral therapy